Lancet Neurology. 2018;17(2):153–161.
63. Parkinson’s disease insight report. Wilmington Healthcare. https:// wilmingtonhealthcare. com/what-we-do/nhs-service-improvement/ parkinsons-disease-insight-report. Accessed May 19, 2019.
64. Allen NE, Schwarzel AK, Canning CG. Recurrent falls in Parkinson’s disease: a systematic review. Journal of Parkinsons Disease. 2013;2013:906274.
65. Walker RW, Chaplin A, Hancock RL, Rutherford R, Gray WK. Hip fractures in people with idiopathic Parkinson’s disease: incidence and outcomes. Movement Disorders. 2013;28(3):334–340; Kalilani L, Asgharnejad M, Palokangas T, Durgin T. Comparing the incidence of falls/fractures in Parkinson’s disease patients in the US population. PLOS ONE. 2016;11(9): e0161689-e0161689.
66. Li F, Harmer P, Fitzgerald K, et al. Tai chi and postural stability in patients with Parkinson’s disease. New England Journal of Medicine. 2012;366(6):511–519; Ypinga JHL, de Vries NM, Boonen LHHM, et al. Effectiveness and costs of specialised physiotherapy given via ParkinsonNet: a retrospective analysis of medical claims data. Lancet Neurology. 2018;17(2):153–161; van der Marck MA, Klok MPC, Okun MS, Giladi N, Munneke M, Bloem BR. Consensus-based clinical practice recommendations for the examination and management of falls in patients with Parkinson’s disease. Parkinsonism & Related Disorders. 2014;20(4):360–369.
67. Florence CS, Bergen G, Atherly A, Burns E, Stevens J, Drake C. Medical costs of fatal and nonfatal falls in older adults. Journal of the American Geriatrics Society. 2018;66(4):693–698.
68. Там же.; Kaiser J. Final 2018 budget bill eases biomedical researchers’ policy worries. Science. March 22, 2018. American Association for the Advancement of Science. www.sciencemag.org/news/2018/03/ final-2018-budget-bill-eases-biomedical-researchers-policy-worries. Accessed June 27, 2019.
69. Safarpour D, Thibault DP, DeSanto CL, et al. Nursing home and end-of-life care in Parkinson disease. Neurology. 2015;85(5):413–419.
70. Dorsey ER, George BP, Leff B, Willis AW. The coming crisis: obtaining care for the growing burden of neurodegenerative conditions. Neurology. 2013;80(21):1989–1996; Powell T. New hopes for dementia care. Wall Street Journal. April 11, 2019.
71. Dorsey ER, Topol EJ. State of telehealth. NEJM. 2016;375(2): 154–161.
72. Wilkinson JR, Spindler M, Wood SM, et al. High patient satisfaction with telehealth in Parkinson disease: a randomized controlled study. Neurology Clinical Practice. 2016;6(3):241–251.
73. Telehealth services. In: Medicare Learning Network Booklet. Centers for Medicare & Medicaid Services; 2018.
74. Lacktman NM. Medicare payments for telehealth increased 28 % in 2016: what you should know. Health Care Law Today. August 28, 2017. www. healthcarelawtoday.com/2017/ 08/28/medicare-payments-for-telehealth-increased-28-in-2016-what-you-should-know. Accessed November 2018.
75. Dorsey ER, George BP, Leff B, Willis AW. The coming crisis: obtaining care for the growing burden of neurodegenerative conditions. Neurology. 2013;80(21):1989–1996.
76. Rosenthal E. An American Sickness: How Healthcare Became Big Business and How You Can Take It Back. 1st ed. Penguin Press; 2017; Goodson JD. Unintended consequences of resource-based relative value scale reimbursement. JAMA. 2007;298(19):2308–2310.
77. Rosenthal E. An American Sickness: How Healthcare Became Big Business and How You Can Take It Back. 1st ed. Penguin Press; 2017.
78. Composition of the RVS Update Committee (RUC). American Medical Association. www.ama-assn.org/about/rvs-update-committee-ruc/ composition-rvs-update-committee-ruc. Accessed March 26, 2019.
79. Там же.
80. Там же.; Struhal W, Sellner J, Lisnic V, V6csei L, Muller E, Grisold W. Neurology residency training in Europe – the current situation. European Journal of Neurology. 2011;18(4):e36-e40.
81. Rosenthal E. An American Sickness: How Healthcare Became Big Business and How You Can Take It Back. 1st ed. Penguin Press; 2017.
82. Dorsey ER, George BP, Leff B, Willis AW. The coming crisis: obtaining care for the growing burden of neurodegenerative conditions. Neurology. 2013;80(21):1989–1996.
83. FAQs about the FDA Patient Representative Program. US Food and Drug Administration. www.fda.gov/ForPatients/ucm412529.htm. Updated May 12, 2018. Accessed March 19, 2019.
84. Dorsey ER, George BP, Leff B, Willis AW. The coming crisis: obtaining care for the growing burden of neurodegenerative conditions. Neurology. 2013;80(21):1989–1996; Rosenthal E. An American Sickness: How Healthcare Became Big Business and How You Can Take It Back. 1st ed. Penguin Press; 2017.
85. Historical evolution of FDA advisory committees. In: Rettig RA, Earley LE, Merill RA, eds. Institute of Medicine (US) Committee to Study the Use of Advisory Committees. National Academies Press; 1992.
Глава 8: В будущее с оптимизмом
1. FDA approved drugs for neurology. CenterWatch. www.centerwatch. com/drug-information/fda-approved-drugs/therapeutic-area/10/ neurology. Accessed November 29, 2018.
2. Там же.
3. Инструкция по применению: INBRIJA. US Food and Drug Administration. December 2018. www.accessdata.fda.gov/drugsatfda_ docs/label/2018/209184s000lbl.pdf.
4. Инструкция по применению: GOCOVRI. US Food and Drug Administration. August 2017. www.accessdata.fda.gov/drugsatfda_docs/ label/2017/208944lbl.pdf.
5. Инструкция по применению: XADAGO. US Food and Drug Administration. March 2017. www.accessdata.fda.gov/drugsatfda_docs/label/2017/207145lbl.pdf.
6. Инструкция по применению: NUPLAZID. US Food and Drug Administration. April 2016. www.accessdata.fda.gov/drugsatfda_docs/ label/2016/207318lbl.pdf.
7. Инструкция по применению: DUOPA. US Food and Drug
Administration. September 2016. www.rxabbvie.com/pdf/duopa_pi.pdf.
8. Инструкция по применению: RYTARY. US Food and Drug
Administration. January 2015. www.accessdata.fda.gov/drugsatfda_docs/ label/2015/203312s000lbl.pdf.
9. Инструкция по применению: NORTHERA. US Food and Drug Administration. February 2014. www.accessdata.fda.gov/drugsatfda_ docs/label/2014/203202lbl.pdf.
10. Novartis. Инструкция по применению: EXELON. US Food and Drug Administration. December 2018. www.pharma.us.novartis.com/sites/www.pharma.us.novartis.com/ files/exelon.pdf.
11. Инструкция по применению: NEUPRO. US Food and Drug Administration. April 2012. www.accessdata.fda.gov/drugsatfda_docs/ label/2012/021829s001lbl.pdf.
12. Инструкция по применению: APOKYN. US Food and Drug Administration. July 2014. www.accessdata.fda.gov/drugsatfda_docs/ label/2014/021264s010lbl.pdf.
13. Novartis. Инструкция по применению: COMTAN. US Food and Drug Administration. September 28, 2010. www.accessdata.fda.gov/ drugsatfda_docs/label/2010/020796s15lbl.pdf.
14. FDA approved drugs for neurology. CenterWatch. www.centerwatch. com/drug-information/fda-approved-drugs/therapeutic-area/10/ neurology. Accessed November 29, 2018.
15. Deuschl G, Schade-Brittinger C, Krack P, et al. A randomized trial of deep-brain stimulation for Parkinson’s disease. New England Journal of Medicine. 2006;355(9):896–908.
16. Goetz CG. The history of Parkinson’s disease: early clinical descriptions and neurological therapies. Cold Spring Harbor Perspectives in Medicine. 2011;1(1):a008862; Wagle Shukla A, Okun MS. Surgical treatment of Parkinson’s disease: patients, targets, devices, and approaches. Neurotherapeutics. 2014;11(1):47–59.
17. Wagle Shukla A, Okun MS. Surgical treatment of Parkinson’s disease: patients, targets, devices, and approaches. Neurotherapeutics. 2014;11(1):47–59.
18. Alexander GE, Crutcher MD, DeLong MR. Basal gangliathalamocortical circuits: parallel substrates for motor, oculomotor, “prefrontal” and “limbic” functions. In: Uylings HBM, Van Eden CG, De Bruin JPC, Corner MA, Feenstra MGP, eds. Progress in Brain Research. Vol 85. Elsevier; 1991:119–146; Alexander GE, DeLong MR, Strick PL. Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Annual Review of Neuroscience. 1986;9(1):357–381.
19. Benabid AL, Pollak P, Louveau A, Henry S, de Rougemont J. Combined (thalamotomy and stimulation) stereotactic surgery of the VIM thalamic nucleus for bilateral Parkinson disease. Stereotactic and Functional Neurosurgery. 1987;50(1–6):344–346.
20. Lozano AM, Eltahawy H. How does DBS work? Supplement to Clinical Neurophysiology. 2004;57:733–736.
21. Deuschl G, Schade-Brittinger C, Krack P, et al. A randomized trial of deep-brain stimulation for Parkinson’s disease. New England Journal of Medicine. 2006;355(9):896–908; Follett KA, Weaver FM, Stern M, et al. Pallidal versus subthalamic deep-brain stimulation for Parkinson’s disease. New England Journal of Medicine. 2010;362(22):2077–2091; Benabid AL, Chabardes S, Mitrofanis J, Pollak P. Deep brain stimulation of the subthalamic nucleus for the treatment of Parkinson’s disease. Lancet Neurology. 2009;8(1):67–81; Deep-Brain Stimulation for Parkinson’s Disease Study Group. Deep-brain stimulation of the subthalamic nucleus or the pars interna of the globus pallidus in Parkinson’s disease. New England Journal of Medicine. 2001;345(13):956–963; Weaver FM, Follett K, Stern M, et al. Bilateral deep brain stimulation vs best medical therapy for patients with advanced Parkinson disease: a randomized controlled trial. JAMA. 2009;301(1):63–73; Bronstein JM, Tagliati M, Alterman RL, et al. Deep brain stimulation for Parkinson disease: an expert consensus and review of key issues.